Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-05-20
1996-09-10
Ramsuer, Robert W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514560, 514565, 514551, 514411, 514456, A61K 3122, A61K 31415
Patent
active
055546382
ABSTRACT:
The present invention is directed to the use of an inhibitor of NO activity, such as a nitric oxide scavenger or an NO synthase inhibitor, as an antitumor therapy to reduce tumor blood flow and oxygenation. The invention is also directed to administration of a nitric oxide scavenger or a nitric oxide synthase inhibitor to enhance the effectiveness of tumor therapy with hypoxic or acidic chemotherapeutic agents or hyperthermia. The invention is also directed to the administration of a nitric oxide synthase substrate to a subject previously administered a nitric oxide synthase inhibitor, in order to selectively inhibit tumor perfusion. In a specific example, administration of cell free hemoglobin, a nitric oxide scavenger, in conjunction with mitomycin C, a hypoxic cytotoxin, results in a significant delay in tumor growth of a human tumor xenograft in a mouse compared to mitomycin C alone. In another example, the administration of an inhibitor of nitric oxide synthase followed by the administration of a substrate of the enzyme causes a specific irreversible reduction of tumor blood flow, while normal blood flow is restored.
REFERENCES:
patent: 4001401 (1977-01-01), Bonsen et al.
patent: 4061736 (1977-12-01), Morris et al.
patent: 4301144 (1981-11-01), Iwashita
patent: 4321259 (1982-03-01), Nicolau
patent: 4377512 (1983-03-01), Ajisaka
patent: 4412989 (1983-11-01), Iwashita
patent: 4473563 (1984-09-01), Nicolau
patent: 4584130 (1986-04-01), Bucci et al.
patent: 4598064 (1986-07-01), Walder
patent: 4650786 (1987-03-01), Wong
patent: 4670417 (1987-06-01), Iwasaki
patent: 4710488 (1987-12-01), Wong
patent: 4812449 (1989-03-01), Rideout
patent: 5028588 (1991-07-01), Hoffman et al.
patent: 5266594 (1993-11-01), Dawson et al.
patent: 5273875 (1993-12-01), Griffith
patent: 5296466 (1994-03-01), Kilbourn et al.
patent: 5298490 (1994-03-01), Heavner et al.
patent: 5298506 (1994-03-01), Stamler et al.
patent: 5312835 (1994-05-01), Kilbourn et al.
patent: 5317040 (1994-05-01), Goldman
patent: 5318992 (1994-07-01), Whitten et al.
patent: 5334380 (1994-08-01), Kilbourn et al.
Andrade et al., "Inhibitors of nitric oxide synthase selectively reduce flow in tumou-associated neovasculature", Br. J. Pharmacol. 107:1092-1095, 1992.
Babbs and DeWitt, "Physical principles of local heat therapy for cancer", Med. Instrum. 15:367-373, 1981.
Botstein and Shortle, "Strategies and applications of in vitro mutagenesis", Science 229:1193-1201, 1985.
Brown and Koong, "Therapeutic advantage of hypoxic cells in turmors: a theoretical study", J. Natl. Cancer Inst. 83:178-185, 1991.
Caruthers et al., "New methods for synthesizing deoxyoligonucleotides", Genetic Engineering, J. K. Setlow and A. Hollaender eds., Plenum Press, New York, vol. 4, pp. 1-17, 1982.
Chapman et al., "Keynote address: cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of Hypoxic cells", Int. J. Rad. Oncology, Biol. Phys. 16:911-917, 1987.
Collman et al., "`Picket fence porphyrins.`Synthetic models for oxygen binding proteins", J. Am. Chem. Soc. 97:1427-1439, 1975.
De Venuto et al., "appraisal of hemoglobin solution as a blood substitute", Surgery Gynecology and Obstetrics 149:417-436, 1979.
Dewhirst et al., "The use of hydralazine to manipulate tumour temperatures during hyperthermia", Int. J. Hyperthermia 6:971-983, 1990.
Feola et al., "Development of a bovine stroma-free hemoglobin solution as a blood substitute", Surgery Gynecology and Obstetrics 157:399-408, 1983.
Froehler, "Synthesis of DNA via deoxynucleotide H-phosphonate intermediates", Nucl. Acids Res. 14:5399-5407, 1986.
Hahn and Shiu, "Protein synthesis, thermotolerance and step down heating", Int. J. Radiat. Oncol. Biol. Phys., 11:159-164, 1985.
Hunkapilar et al., "A microbial facility for the analysis and synthesis of genes and proteins", Nature (London) 310:105-111, 1984.
Jain, "Determinants of tumor blood flow: a review", Cancer Res. 48:2641-2658, 1988.
Jones and Howard, "A rapid method for site-specific mutagenesis and directional subcloning by using the polymerase chain reaction to generate recombinant circles", Biotechniques 8:178-180, 1990.
Kilbourne et al., "N.sup.G -Methyl-L-arginine inhibits tumor necrosis factor -induced hypotension: implications for the involvements of nitric oxide", Proc. Natl. Acad. Sci. USA 87:3629-3832, 1990.
Labossiere et al, "Hemoglobin Deer Lodge:.alpha..sub.2 .beta..sub.2 .sup.2 His.fwdarw.Arg ", Clin. Biochem. 5:46-50, 1972.
Martin et al., "The mechanisms by which haemoglobin inhibits the relaxation of rabbit aorta induced by nitrovasodilators, nitric oxide, or bovine retractor penis inhibitory factor", Br. J. Pharmacol. 89:563-571, 1986.
McCormick and Atorssi, "Hemoglobin binding with haptoglobin: delineation of the haptoglobin binding site on the .alpha.-chain of human hemoglobin", J. Prot. Chem. 9:735, 1990.
Merrifield, "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide", J. Chem. Soc. 85:2149-2154, 1963.
Moncada et al., "Nitric oxide: physiology, pathophysiology, and pharmacology", Pharm. Rev. 43:109-142, 1991.
Perutz, "Mechanism of denaturation of haemoglobin by alkali", Nature 247:341, 1974.
Prescott et al., "Use of Nitroprusside to increase tissue temperature during local hyperthermia in normal and tumor-bearing dogs", Int. J. Hyperthermia 23:377-385, 1990.
Radomski et al., "Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets", Cancer Res. 51:6073-6078, 1991.
Robbins and Angell, Basic Pathology, 2d Ed., W. B. Saunders Co., Philadelphia, pp. 68-79, 1976.
Sehgal et al., "Polymerized pyrodoxylated hemoglobin: a red cell substitute with normal oxygen capacity", Surgery 95:433-438, 1984.
Sevick and Jain, "Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure", Cancer Res. 49:3506-3512, 1989.
Tentori et al., "Hemoglobin Abruzzo: beta 143(H21) His.fwdarw.Arg", Clin. Chim. Acta 38:258-262, 1972.
Traylor and Traylor, "Considerations for the design of useful synthetic oxygen carriers", Ann. Rev. Biophys. Bioeng. 11:105-127, 1982.
Winslow et al., "Hemoglobin McKees Rocks(.alpha..sub.2 .beta..sub. .sup.145 Tyr.fwdarw.Term ", J. Clin. Invest. 57:772-781, 1976.
Wood et al., "Changes in tumour phosphorus metabolism by the nitric oxide donor sin-1", abstract presented at 41st Ann. Meeting of Radiation Research Society, Dallas, Texas, Mar. 20-25, 1993.
Zoller and Smith, "Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-Stranded DNA template DNA template", DNA 3:479-488, 1984.
Chen et al., 1981, "Microvacular rarefaction in spontaneously hypertensive rat cremaster muscle", Am. J. Physiol. 241:H306-H310.
Hilf et al., 1965, "Biochemical and morphologic properties of a new lactating mammary tumor line in the rat," Cancer Res. 25;286-299.
Papenfuss et al., 1979, "A transparent access chamber for the rat dorsal skin fold," Microvacular Res. 18:311-318.
Tompkins et al., 1974, "Velocity measurement by self-tracking correlator," Rev. Sci. Instrum. 45:647-649.
Wood et al., 1994, "The NO synthase inhibitor nitro-L-arginine alters tumor metabolism, and response to X-rays and bioreductive drugs," 42nd Annual Meeting of Radiation Research Society and the 14th Ann. Meeting, North American Hyperthermia Society, Apr. 29-May 4, Nashville, TN.
Brizel et al., 1994, Int. J. Radiation Oncology Biol. Phys. 30:635-642.
W. A. Denny, 1995, "Bioreductive Drugs: A unique opportunity for de novo design."Ninth Intl. Conference on Chemical Modifier of Cancer Treatment, abstr. p. 33.
Gatenby et al., 1988, "Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy." Int. J. Radiation Oncology Biol. Phys. 14:831-838.
Hockel et al., 1993, "Intratumoral pO.sub.2 predicts survival in advanced cancer of the uterine cervix." Radiotherapy and Oncology 26:45-50.
R. K. Jain, 1989, "Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies," J. Natl. Cancer Inst. 81:570-576
Bonaventura Joseph
DeAngelo Joseph
Dewhirst Mark W.
Meyer Robert E.
Apex Bioscience, Inc.
Duke University
North Carolina State University
Peabody John
Ramsuer Robert W.
LandOfFree
Methods for improving therapeutic effectiveness of agents for th does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for improving therapeutic effectiveness of agents for th, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for improving therapeutic effectiveness of agents for th will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1320830